MedTrace Logo

Safety Study of Multiple Peptide Vaccine to Esophageal Cancer

NCT00561275 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 6

Last updated 2008-07-15

No results posted yet for this study

Summary

This is a phase 1 study of multiple peptide vaccine therapy and GM-CSF in treating patients with esophageal cancer.

Conditions

  • Esophageal Cancer

Interventions

BIOLOGICAL

LY6K, VEGFR1, VEGFR2

1 mg/body every two week with GM-CSF, 4 cycles

Sponsors & Collaborators

  • Human Genome Center, Institute of Medical Science, University of Tokyo

    collaborator OTHER

  • Japanese Foundation for Cancer Research

    lead OTHER

Principal Investigators

  • Takuya Takayama, M.D.Ph.D · Cancer Institute of Japanese Foundation for Cancer Research

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
20 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-10-31
Primary Completion
2008-05-31
Completion
2008-06-30

Countries

  • Japan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00561275 on ClinicalTrials.gov